GlucoTrack (GCTK) Competitors

$0.67 -0.03 (-4.30%)

Closing price 04:00 PM Eastern

Extended Trading

$0.67 +0.00 (+0.16%)

As of 05:54 PM Eastern

GCTK vs. LUCY, NDRA, CLGN, CODX, and ITOC

Should you buy GlucoTrack stock or one of its competitors? MarketBeat compares GlucoTrack with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GlucoTrack include Innovative Eyewear (LUCY), ENDRA Life Sciences (NDRA), CollPlant Biotechnologies (CLGN), Co-Diagnostics (CODX), and Itonic (ITOC). These companies are all part of the "medical equipment" industry.

How does GlucoTrack compare to Innovative Eyewear?

Innovative Eyewear (NASDAQ:LUCY) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

In the previous week, GlucoTrack had 2 more articles in the media than Innovative Eyewear. MarketBeat recorded 7 mentions for GlucoTrack and 5 mentions for Innovative Eyewear. Innovative Eyewear's average media sentiment score of 1.45 beat GlucoTrack's score of 0.31 indicating that Innovative Eyewear is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innovative Eyewear	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GlucoTrack	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.0% of Innovative Eyewear shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 1.7% of Innovative Eyewear shares are held by company insiders. Comparatively, 2.2% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innovative Eyewear	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GlucoTrack has a net margin of 0.00% compared to Innovative Eyewear's net margin of -285.16%. Innovative Eyewear's return on equity of -79.72% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innovative Eyewear	-285.16%	-79.72%	-73.71%
GlucoTrack	N/A	-324.84%	-178.16%

Innovative Eyewear has higher revenue and earnings than GlucoTrack. Innovative Eyewear is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innovative Eyewear	$2.66M	2.39	-$7.59M	-$2.04	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$55.51	N/A

Innovative Eyewear has a beta of 2.7, indicating that its stock price is 170% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Summary

Innovative Eyewear beats GlucoTrack on 7 of the 12 factors compared between the two stocks.

How does GlucoTrack compare to ENDRA Life Sciences?

ENDRA Life Sciences (NASDAQ:NDRA) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, GlucoTrack had 3 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 7 mentions for GlucoTrack and 4 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 0.63 beat GlucoTrack's score of 0.31 indicating that ENDRA Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ENDRA Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GlucoTrack	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GlucoTrack's return on equity of -324.84% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-397.71%	-190.73%
GlucoTrack	N/A	-324.84%	-178.16%

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.92	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$55.51	N/A

ENDRA Life Sciences has a beta of -0.11, indicating that its share price is 111% less volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

ENDRA Life Sciences presently has a consensus target price of $30.00, indicating a potential upside of 422.65%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 2.2% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

ENDRA Life Sciences beats GlucoTrack on 7 of the 13 factors compared between the two stocks.

How does GlucoTrack compare to CollPlant Biotechnologies?

CollPlant Biotechnologies (NASDAQ:CLGN) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

GlucoTrack has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -353.70%. CollPlant Biotechnologies' return on equity of -161.69% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-353.70%	-161.69%	-109.44%
GlucoTrack	N/A	-324.84%	-178.16%

21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by insiders. Comparatively, 2.2% of GlucoTrack shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CollPlant Biotechnologies has higher revenue and earnings than GlucoTrack. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.55	-$11.49M	-$1.35	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$55.51	N/A

CollPlant Biotechnologies has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

In the previous week, GlucoTrack had 5 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 7 mentions for GlucoTrack and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.94 beat GlucoTrack's score of 0.31 indicating that CollPlant Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GlucoTrack	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CollPlant Biotechnologies currently has a consensus price target of $11.50, indicating a potential upside of 2,640.05%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, research analysts clearly believe CollPlant Biotechnologies is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CollPlant Biotechnologies beats GlucoTrack on 12 of the 15 factors compared between the two stocks.

How does GlucoTrack compare to Co-Diagnostics?

Co-Diagnostics (NASDAQ:CODX) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

GlucoTrack has a net margin of 0.00% compared to Co-Diagnostics' net margin of -7,546.43%. Co-Diagnostics' return on equity of -125.46% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-7,546.43%	-125.46%	-109.64%
GlucoTrack	N/A	-324.84%	-178.16%

GlucoTrack has lower revenue, but higher earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$622.49K	9.43	-$46.90M	-$29.73	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$55.51	N/A

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 5.4% of Co-Diagnostics shares are owned by company insiders. Comparatively, 2.2% of GlucoTrack shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Co-Diagnostics had 1 more articles in the media than GlucoTrack. MarketBeat recorded 8 mentions for Co-Diagnostics and 7 mentions for GlucoTrack. Co-Diagnostics' average media sentiment score of 0.33 beat GlucoTrack's score of 0.31 indicating that Co-Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GlucoTrack	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Co-Diagnostics presently has a consensus price target of $67.50, indicating a potential upside of 4,041.10%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Co-Diagnostics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Summary

Co-Diagnostics beats GlucoTrack on 12 of the 15 factors compared between the two stocks.

How does GlucoTrack compare to Itonic?

Itonic (NASDAQ:ITOC) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Itonic's return on equity of 0.00% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Itonic	N/A	N/A	N/A
GlucoTrack	N/A	-324.84%	-178.16%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Itonic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Itonic has a beta of 3.23, suggesting that its stock price is 223% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

In the previous week, GlucoTrack had 5 more articles in the media than Itonic. MarketBeat recorded 7 mentions for GlucoTrack and 2 mentions for Itonic. Itonic's average media sentiment score of 0.44 beat GlucoTrack's score of 0.31 indicating that Itonic is being referred to more favorably in the media.

Company	Overall Sentiment
Itonic	Neutral
GlucoTrack	Neutral

10.9% of GlucoTrack shares are owned by institutional investors. 2.2% of GlucoTrack shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Itonic has higher revenue and earnings than GlucoTrack.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Itonic	$523.03K	10.14	-$5.10M	N/A	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$55.51	N/A

Summary

Itonic beats GlucoTrack on 6 of the 9 factors compared between the two stocks.

Get GlucoTrack News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GCTK vs. The Competition

Export

Metric	GlucoTrack	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.30M	$8.00B	$6.29B	$12.46B
Dividend Yield	N/A	2.50%	2.79%	5.30%
P/E Ratio	-0.01	18.40	20.87	25.58
Price / Sales	N/A	7.70	521.63	63.56
Price / Cash	N/A	16.76	42.94	55.34
Price / Book	0.24	3.68	9.86	6.70
Net Income	-$19.39M	$223.05M	$3.55B	$333.77M
7 Day Performance	-22.10%	-2.09%	-0.32%	0.45%
1 Month Performance	-8.83%	3.45%	1.34%	4.06%
1 Year Performance	-92.54%	2.02%	41.03%	36.21%

GlucoTrack Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GCTK GlucoTrack	0.3849 of 5 stars	$0.67 -4.3%	N/A	-92.0%	$1.30M	N/A	N/A	5	News Coverage Earnings Report Short Interest Increase Gap Down
LUCY Innovative Eyewear	1.1209 of 5 stars	$1.05 +2.4%	N/A	-49.7%	$6.62M	$2.66M	N/A	9	News Coverage Earnings Report Upcoming Earnings Short Interest Decrease Gap Up
NDRA ENDRA Life Sciences	2.8872 of 5 stars	$4.86 +0.2%	$30.00 +517.3%	+79.1%	$6.03M	N/A	N/A	20	News Coverage Upcoming Earnings
CLGN CollPlant Biotechnologies	2.4163 of 5 stars	$0.41 +3.2%	$11.50 +2,684.5%	-73.0%	$5.95M	$2.37M	N/A	70	News Coverage Upcoming Earnings Gap Up
CODX Co-Diagnostics	1.9484 of 5 stars	$1.64 +3.1%	$67.50 +4,015.9%	-85.3%	$5.90M	$620K	N/A	100	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GCTK) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GlucoTrack (GCTK) Competitors

GCTK vs. LUCY, NDRA, CLGN, CODX, and ITOC

How does GlucoTrack compare to Innovative Eyewear?

Summary

How does GlucoTrack compare to ENDRA Life Sciences?

Summary

How does GlucoTrack compare to CollPlant Biotechnologies?

Summary

How does GlucoTrack compare to Co-Diagnostics?

Summary

How does GlucoTrack compare to Itonic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GlucoTrack (GCTK) Competitors

GCTK vs. LUCY, NDRA, CLGN, CODX, and ITOC

How does GlucoTrack compare to Innovative Eyewear?

Does the media prefer LUCY or GCTK?

Do institutionals & insiders have more ownership in LUCY or GCTK?

Do analysts rate LUCY or GCTK?

Is LUCY or GCTK more profitable?

Which has better valuation and earnings, LUCY or GCTK?

Which has more volatility and risk, LUCY or GCTK?

Summary

How does GlucoTrack compare to ENDRA Life Sciences?

Does the media favor NDRA or GCTK?

Is NDRA or GCTK more profitable?

Which has better valuation & earnings, NDRA or GCTK?

Which has more volatility and risk, NDRA or GCTK?

Do analysts rate NDRA or GCTK?

Do institutionals & insiders believe in NDRA or GCTK?

Summary

How does GlucoTrack compare to CollPlant Biotechnologies?

Is CLGN or GCTK more profitable?

Do institutionals & insiders believe in CLGN or GCTK?

Which has stronger earnings and valuation, CLGN or GCTK?

Which has more risk & volatility, CLGN or GCTK?

Does the media prefer CLGN or GCTK?

Do analysts recommend CLGN or GCTK?

Summary

How does GlucoTrack compare to Co-Diagnostics?

Is CODX or GCTK more profitable?

Which has preferable valuation and earnings, CODX or GCTK?

Do institutionals and insiders believe in CODX or GCTK?

Does the media refer more to CODX or GCTK?

Do analysts rate CODX or GCTK?

Which has more risk and volatility, CODX or GCTK?

Summary

How does GlucoTrack compare to Itonic?

Is ITOC or GCTK more profitable?

Do analysts rate ITOC or GCTK?

Which has more volatility & risk, ITOC or GCTK?

Does the media favor ITOC or GCTK?

Do institutionals and insiders hold more shares of ITOC or GCTK?

Which has higher earnings & valuation, ITOC or GCTK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools